Stryker to acquire spinal device maker for $1.4 billion

So far this year, the volume has averaged about 370,364 shares. He has formerly spent over 5 years as a trader in U.S. stock market and is now semi-stepped down. Now the market price is up 19% on the year and up 52.78% YTD. For this KTWO's 20 days and 50 days MA (moving average) comparison clear the blur picture. When the price over the last 200 days is moving with increasing trend, look for buy opportunities and when it shows decreasing trend the price is below the last 200 days, look for sell opportunities. The Company's complex spine products include EVEREST, MESA, MESA 2, and DENALI deformity spinal systems; NILE alternative fixation systems; MESA rail deformity spinal systems; Cricket and Quicket deformity systems; CAPRI corpectomy cage systems; MESA small stature, rail small stature, and mini spinal systems; SERENGETI complex spine minimally invasive retractor systems; RAVINE complex spine lateral access systems; and SANTORINI corpectomy cage systems. On a downside, the stock is likely to find some support, which begins at $27.36.

K2M Group Holdings (KTWO) stock gained attention from Active Investors. The stock also has a beta of 1.46. How much shares are traded? $54.66M as of today. The second largest holder, Waddell & Reed Financial Inc, with 2.22M shares which equates to $49.97M worth of the stock. In the terms of the acquisition, K2M is to become a wholly owned subsidiary of Stryker at the aquisition price of $27.50 per share, generating a total value in the region of $1.4 billion.

Johnathan focuses on breaking news stories and ensuring we offer timely reporting on some of the most recent stories released through market wires about finance Sector companies. After making this transaction, the Global Accounting Officer owns a direct stake of 14,032 shares, worth $623,013, as per the last closing price.

CFO, Cole Gregory S had divested 867 shares for $67,139 through a trade on 2018/07/03.

However out of 7 analysts 1 suggest K2M Group Hldngs Cmn (NASDAQ:KTWO) a Strong Buy, 6 suggested Buy, 1 Hold and 0 Sell, while 0 analysts recommend the stock a Strong Sell. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future.


Analysts contributed mean rating at 2. Finally, Cantor Fitzgerald reaffirmed a "buy" rating and issued a $28.00 price objective on shares of K2M Group in a research report on Thursday. Analysts therefore consider the investment a net gain. Needham, reiterated their call for Buy, on January 09. K2M Group Holdings had 3 analyst reports since March 1, 2018 according to SRatingsIntel. KTWO's ROE is -16.3%, which is also considerably worse than the industry's ROE of 17.42%. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.48 and a quick ratio of 2.13. The stock has a debt/capital of 0.52.

Shares of K2M Group Holdings, Inc.

Keeping close watch on fundamental and technical data, K2M Group Holdings, Inc. The medical device company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.06). KTWO has diverse figures for different time frames; starting from week's performance it is giving positive returns of 23.82% in last five regular trading sessions. During the same period a year ago, the company earned ($0.21) EPS. That was worse than consensus for -$0.19. Revenue for the recent quarter stood at $73.58 million, up 12% on a year ago and above the $70.85 million predicted by analysts. The business had revenue of $73.58 million during the quarter, compared to analysts' expectations of $70.85 million.

EPS Growth Rate: REIS's 0% versus KTWO's 11%.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.